Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Cedars-Sinai Medical Center
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop
into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who
have myelodysplastic syndrome.
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow
and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them
from dividing. Giving paricalcitol together with gemcitabine may be an effective treatment
PURPOSE: This phase I trial is studying the side effects and best dose of paricalcitol when
given together with gemcitabine in treating patients with advanced cancer.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.